针对骨生理学治疗转移性前列腺癌。
Targeting bone physiology for the treatment of metastatic prostate cancer.
作者信息
Autio Karen A, Morris Michael J
机构信息
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
出版信息
Clin Adv Hematol Oncol. 2013 Mar;11(3):134-43.
Abstract
Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression. This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.
摘要
转移性前列腺癌对骨骼有独特的偏好，可导致严重的临床后果，如骨折和脊髓压迫。这种对骨骼的趋向性不仅带来了临床挑战，也为了解骨内肿瘤生物学及制定相关治疗策略提供了机会。肿瘤细胞迁移至骨骼、保持休眠状态，然后定植并扩散的过程，基于前列腺癌肿瘤细胞与宿主微环境之间的复杂相互作用。本文综述将概述这些相互作用以及针对去势抵抗性前列腺癌骨转移的治疗方法。
相似文献
1
Targeting bone physiology for the treatment of metastatic prostate cancer.
Clin Adv Hematol Oncol. 2013 Mar;11(3):134-43.
2
Bone-targeting agents in prostate cancer.
Cancer Metastasis Rev. 2014 Sep;33(2-3):619-28. doi: 10.1007/s10555-013-9480-2.
3
Bone targeted therapies in metastatic castration-resistant prostate cancer.
Cancer J. 2013 Jan-Feb;19(1):66-70. doi: 10.1097/PPO.0b013e31827f123e.
4
Bone metastases in prostate cancer: a targeted approach.
Curr Opin Oncol. 2007 May;19(3):254-8. doi: 10.1097/CCO.0b013e32805e8787.
5
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
J Clin Oncol. 2005 Nov 10;23(32):8232-41. doi: 10.1200/JCO.2005.03.0841.
6
Current trials using bone-targeting agents in prostate cancer.
Cancer J. 2008 Jan-Feb;14(1):35-9. doi: 10.1097/PPO.0b013e318161d32d.
7
Clinical approaches to osseous metastases in prostate cancer.
Oncologist. 2003;8(2):161-73. doi: 10.1634/theoncologist.8-2-161.
8
Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.
Asian J Androl. 2011 Nov;13(6):783-4. doi: 10.1038/aja.2011.120. Epub 2011 Aug 22.
9
Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.
Ann Oncol. 2012 May;23(5):1085-1094. doi: 10.1093/annonc/mdr573. Epub 2012 Jan 20.
10
Recent advances in bone-targeted therapies of metastatic prostate cancer.
Cancer Treat Rev. 2014 Jul;40(6):730-8. doi: 10.1016/j.ctrv.2014.04.003. Epub 2014 Apr 16.
引用本文的文献
1
The Tight Relationship Between the Tumoral Microenvironment and Radium-223.
Biomedicines. 2025 Feb 12;13(2):456. doi: 10.3390/biomedicines13020456.
2
Primary and Metastatic Bone Tumors of the Patella: Literature Review and Institutional Experience.
Arch Bone Jt Surg. 2022 Feb;10(2):190-203. doi: 10.22038/abjs.2021.53494.2655.
3
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.
J Exp Clin Cancer Res. 2017 Aug 11;36(1):108. doi: 10.1186/s13046-017-0578-1.
4
The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.
Curr Osteoporos Rep. 2016 Oct;14(5):170-7. doi: 10.1007/s11914-016-0323-2.
5
Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.
J Transl Med. 2016 Apr 27;14:102. doi: 10.1186/s12967-016-0868-y.
6
Osteoclast derivation from mouse bone marrow.
J Vis Exp. 2014 Nov 6(93):e52056. doi: 10.3791/52056.
本文引用的文献
1
CXCR4 expression in prostate cancer progenitor cells.
PLoS One. 2012;7(2):e31226. doi: 10.1371/journal.pone.0031226. Epub 2012 Feb 16.
2
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Eur J Cancer. 2012 Mar;48(5):678-86. doi: 10.1016/j.ejca.2011.12.023. Epub 2012 Feb 15.
3
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
Mol Cell Endocrinol. 2012 Apr 4;351(2):249-63. doi: 10.1016/j.mce.2011.12.015. Epub 2012 Jan 8.
4
Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.
5
Treatment of prostate cancer metastases: more than semantics.
Lancet. 2012 Jan 7;379(9810):4-6. doi: 10.1016/S0140-6736(11)61540-7. Epub 2011 Nov 15.
6
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15.
7
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Ann Oncol. 2012 May;23(5):1341-1347. doi: 10.1093/annonc/mdr435. Epub 2011 Oct 10.
8
Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer.
Am J Pathol. 2011 Nov;179(5):2559-68. doi: 10.1016/j.ajpath.2011.07.011. Epub 2011 Sep 9.
9
Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression.
PLoS One. 2011;6(5):e20164. doi: 10.1371/journal.pone.0020164. Epub 2011 May 23.
10
Cancer to bone: a fatal attraction.
Nat Rev Cancer. 2011 Jun;11(6):411-25. doi: 10.1038/nrc3055. Epub 2011 May 19.
Zotero 插件